Novel insights into mesothelioma biology and implications for therapy
Malignant mesothelioma is a universally lethal cancer that is increasing in incidence
worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and …
worldwide. There is a dearth of effective therapies, with only one treatment (pemetrexed and …
A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti–PD-1 agent pembrolizumab
PS Adusumilli, MG Zauderer, I Rivière, SB Solomon… - Cancer discovery, 2021 - AACR
Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant
pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response …
pleural mesothelioma (MPM), are aggressive solid tumors with poor therapeutic response …
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind …
M Maio, A Scherpereel, L Calabrò, J Aerts… - The Lancet …, 2017 - thelancet.com
Background New therapeutic strategies for malignant mesothelioma are urgently needed. In
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated …
[HTML][HTML] Systematic review of trimodality therapy for patients with malignant pleural mesothelioma
C Cao, D Tian, C Manganas, P Matthews… - Annals of …, 2012 - ncbi.nlm.nih.gov
Background Malignant pleural mesothelioma (MPM) is an aggressive form of cancer arising
from the pleural mesothelium. Trimodality therapy (TMT) involving extrapleural …
from the pleural mesothelium. Trimodality therapy (TMT) involving extrapleural …
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study
L Calabrò, A Morra, D Giannarelli, G Amato… - The Lancet …, 2018 - thelancet.com
Background Tremelimumab, an anti-CTLA4 monoclonal antibody, initially showed good
activity when used alone in patients with mesothelioma, but did not improve the overall …
activity when used alone in patients with mesothelioma, but did not improve the overall …
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity
PS Adusumilli, L Cherkassky… - Science translational …, 2014 - science.org
Translating the recent success of chimeric antigen receptor (CAR) T cell therapy for
hematological malignancies to solid tumors will necessitate overcoming several obstacles …
hematological malignancies to solid tumors will necessitate overcoming several obstacles …
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: a comprehensive analysis reveals prognostic immune markers
Antitumor immune responses against solid malignancies correlate with improved patient
survival. We conducted a comprehensive investigation of immune responses in tumor and …
survival. We conducted a comprehensive investigation of immune responses in tumor and …
[HTML][HTML] Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor …
Background Tumor immune microenvironment (TME) plays a key role in malignant pleural
mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune …
mesothelioma (MPM) pathogenesis and treatment outcome, supporting a role of immune …
Secreted primary human malignant mesothelioma exosome signature reflects oncogenic cargo
Malignant mesothelioma (MM) is a highly-aggressive heterogeneous malignancy, typically
diagnosed at advanced stage. An important area of mesothelioma biology and progression …
diagnosed at advanced stage. An important area of mesothelioma biology and progression …
Heterogeneity in immune cell content in malignant pleural mesothelioma
J Minnema-Luiting, H Vroman, J Aerts… - International journal of …, 2018 - mdpi.com
Malignant pleural mesothelioma (MPM) is a highly aggressive cancer with limited therapy
options and dismal prognosis. In recent years, the role of immune cells within the tumor …
options and dismal prognosis. In recent years, the role of immune cells within the tumor …